BioSpace News Archive

Despite being the largest minority group in the United States, the contributions of disabled people are remarkedly underreported in the life sciences industry.

89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.

Amarin Corporation plc announced that new REDUCE-IT data show that VASCEPA/VAZKEPA significantly reduced cardiovascular events in patients with a history of smoking.

Medtronic plc, a global leader in healthcare technology, announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial.

Bayer announced the start of a Phase III clinical development program “OCEANIC” to investigate the efficacy and safety of asundexian, an investigational oral Factor XIa inhibitor, in patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.